聂勇战 Yongzhan Nie

国家级人才，担任西京医院消化内科副主任、肿瘤生物学国家重点实验室常务副主任、中国抗癌协会副秘书长兼整合肿瘤学分会主任委员、陕西省抗癌协会副理事长。以第一负责人主持国家十三五重点研发计划慢病项目、国家自然科学基金重点项目、国家杰出青年科学基金项目、国家自然科学基金国际（合作）及交流项目等课题10项，总经费2400余万元。以第一完成人获得2017年度中国抗癌协会科技奖一等奖，并获得国家科技进步创新团队奖（2016 5/15）。发表论文190篇，被引用4408次，以第一作者、通讯作者或共同通讯作者发表论文54篇，近五年来在Autophagy、Journal of Cell Biology、Oncogene等杂志发表SCI论著33篇。编写教材4部，担任国家十二五规范化教材《内科学》副主编；申请专利13项，其中PCT专利2项，获批4项。研究方向：主要研究方向为胃肠道肿瘤标志物发现和临床应用、肿瘤耐药和转移机制与肝脏能量代谢研究。坚持临床与基础紧密结合，围绕胃癌发生发展的调控机制展开研究，发现了一组与胃癌发生发展密切相关的关键分子，并在此基础上开展了以MG7、RNF180、Septin9为代表的胃癌预警、临床诊断和治疗新技术应用研究。

National-level talent, serving as Deputy Director of the Department of Gastroenterology at Xijing Hospital, Executive Deputy Director of the State Key Laboratory of Cancer Biology, Deputy Secretary-General and Chairman of the Integrative Oncology Branch of the Chinese Anti-Cancer Association, and Vice President of the Shaanxi Anti-Cancer Association. As the principal investigator, he leads 10 projects including the National 13th Five-Year Key R&D Program for Chronic Diseases, National Natural Science Foundation Key Projects, National Science Fund for Distinguished Young Scholars, and National Natural Science Foundation International (Cooperation) and Exchange Projects, with total funding exceeding 24 million yuan. As the first contributor, he received the First Prize of the Science and Technology Award of the Chinese Anti-Cancer Association in 2017, and the National Science and Technology Progress Innovation Team Award (2016, 5/15). He has published 190 papers with 4,408 citations, including 54 papers as first author, corresponding author, or co-corresponding author. In the past five years, he has published 33 SCI papers in journals such as Autophagy, Journal of Cell Biology, and Oncogene. He has compiled 4 textbooks and served as associate editor of the national standardized textbook “Internal Medicine” for the 12th Five-Year Plan; applied for 13 patents, including 2 PCT patents, with 4 approved. Research directions: Main research focuses on discovery and clinical application of gastrointestinal tumor biomarkers, tumor drug resistance and metastasis mechanisms, and liver energy metabolism research. Adhering to the close integration of clinical practice and basic research, his work focuses on the regulatory mechanisms of gastric cancer development, discovering a group of key molecules closely related to gastric cancer occurrence and development, and conducting application research on new technologies for gastric cancer early warning, clinical diagnosis, and treatment represented by MG7, RNF180, and Septin9.